Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent (NYSE: A) named Michael Buckner as chief legal officer, effective May 4, 2026. Buckner brings nearly three decades of senior global legal experience across mergers and acquisitions, antitrust, intellectual property and regulatory matters.
He joins from Danaher, where he led M&A legal strategy including the Abcam acquisition and Veralto spin-off. Agilent reported fiscal 2025 revenue of $6.95 billion and about 18,000 employees.
Agilent (NYSE: A) will report second-quarter fiscal 2026 results after the market close on May 27, 2026 and will host a listen-only conference call webcast at 1:30 p.m. PDT the same day. A recording will be available on the investor website for 90 days.
Agilent reported $6.95 billion revenue for fiscal 2025 and employs about 18,000 people worldwide. Webcast access is via the Events section of Agilent's Investor Relations site.
TORM plc (A) held its Annual General Meeting on 15 April 2026 where all resolutions were passed on a poll with 52.83% turnout (53,955,672 votes of 102,123,339 eligible).
Notable outcomes: Annual Report approved, auditor reappointed, buyback resolutions passed (Contract A: 99.59% for; Contract B: 73.30% for), and the Board confirmed quarterly dividend policy and a Q4 interim dividend paid 25 March 2026.
The Board noted >20% votes against Resolutions 2, 3 and 12 and will consult shareholders to understand concerns.
Agilent (NYSE: A) will showcase cancer research solutions at the AACR Annual Meeting in San Diego, April 17–22, 2026. Highlights include the new BioTek Cytation 9, an AI-enabled preview for xCELLigence RTCA eSight, SureSelect compatibility with Oxford Nanopore long-read sequencing, and user events.
Agilent will exhibit at booth 4527 and continue support for early-career researchers via AACR Foundation initiatives.
Crawford & Company (NYSE: A) named Jemin Thakkar global chief information officer, effective April 1, 2026. Thakkar will report to President & CEO Bruce Swain and lead Crawford’s global IT and technology organization, expanding his prior role as chief information security officer.
The reorganization centralizes IT governance, aims to improve data integration and analytics, clarify accountability for technology investments, accelerate enterprise modernization, and responsibly advance AI with disciplined data and security practices.
Agilent (NYSE: A) on April 1, 2026 announced the BioTek Cytation 9, a new cell imaging multimode reader combining multimode microplate detection with high-content imaging in one platform.
Cytation 9 adds inverted fluorescence and upright imaging optics, a multimode reader module, and claims twice the imaging speed, targeting higher-throughput cell‑based and biochemical workflows for research and drug discovery.
TORM plc (NASDAQ: TRMD A) increased share capital by 43,697 A-shares following exercise of Restricted Share Units on March 31, 2026. 10,634 shares were subscribed at DKK 131.80 and 33,063 at DKK 148.70. Post-issue share capital is USD 1,021,233.39 across 102,123,339 A-shares.
New shares are ordinary, carry dividend and voting rights from issuance, and are expected to list on Nasdaq Copenhagen as soon as possible.
Agilent (NYSE: A) announced FDA approval on March 26, 2026 for PD-L1 IHC 22C3 pharmDx, Code SK006 as a companion diagnostic to identify esophageal or gastroesophageal junction (GEJ) carcinoma patients with PD-L1 CPS ≥ 1 who may be eligible for treatment with KEYTRUDA.
This marks the eighth FDA companion diagnostic indication for 22C3. Agilent reported $6.95 billion revenue for fiscal 2025 and ~18,000 employees.
TORM plc (NASDAQ: TRMD A) increased its share capital by 42,533 A-shares following exercise of Restricted Share Units on March 24, 2026. The new shares were subscribed in cash at DKK 148.70 and correspond to a nominal value of USD 425.33.
After the issue, share capital totals USD 1,020,796.42, divided into 102,079,642 A-shares with a nominal value of USD 0.01 each. The shares carry one vote and are expected to be admitted to trading on Nasdaq Copenhagen.
Crawford & Company (NYSE:A) named W. Bruce Swain Jr. president and chief executive officer, effective immediately on March 23, 2026.
Swain served as interim CEO since January 1, 2026, has more than three decades at Crawford including 19 years as CFO, and will remain on the board. Jesse Crawford Sr. will not stand for reelection at the Annual Shareholder Meeting on May 14, 2026, and will become an honorary board member and emeritus officer after the ASM.